On May 29, 2019 Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, reported that it will be presenting preclinical data for its Cargocyte technology platform program targeting difficult to treat Breast Cancer at the BIO International Convention meeting June 3-6 in Philadelphia, PA (Press release, Cytonus Therapeutics, MAY 29, 2019, View Source [SID1234536663]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
"We are honored to have been selected to present Cytonus’ first-of-its-kind Cargocyte technology platform at this year’s BIO convention and look forward to sharing our promising CA-IL12 data in treating Triple Negative Breast Cancer in preclinical animal models," said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus.
Details of the presentation:
Company Name: Cytonus Therapeutics, Inc.
Presentation Date: Thursday, June 6
Presentation Time: 1:30:00 PM
Presentation Room: Theater 1
Speaker: Remo Moomiaie-Qajar, M.D., CEO